Final Thoughts on Improving Outcomes in CRC

In the final segment of the discussion, the expert panel shares their thoughts on the current state of treatment for patients with metastatic colorectal cancer (mCRC).

Dan Haller, MD, explains that overall survival for mCRC has improved 5-fold since he trained as a fellow, back when there was only fluorouracil; in fact, some patients with metastatic disease are now being cured. It’s important to realize how far we’ve come, he comments.

Axel Grothey, MD, says there is no clear winner when it comes to choosing first-line therapy for mCRC. There are several options, and it’s not a one-size-fits-all scenario. The next generation of big questions will be answered by diving into the subset analyses of large phase III studies, he suggests.